Cited by 3,207Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Open access

Amado, Rafael G., Wolf, Michael, Peeters, Marc, Van Cutsem, Eric, Siena, Salvatore, Freeman, Daniel J., Juan, Todd, Sikorski, Robert, Suggs, Sid, Radinsky, Robert, Patterson, Scott D., Chang, David D.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.7116

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.7116

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 401–500 of 1,014

Quantifying factors for the success of stratified medicine
Trusheim, M. R., Burgess, B., Hu, S. X., Long, T., Averbuch, S. D., Flynn, A. A., Lieftucht, A., Mazumder, A., Milloy, J., Shaw, P. M., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3557 · Cited by 104
Pharmacogenomic biomarkers: new tools in current and future drug therapy
Sim, S. C., & Ingelman‐Sundberg, M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.008 · Cited by 106
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
Boland, W., & Bebb, G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903110709 · Cited by 102
Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality
Divitiis, C. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15049 · Cited by 108
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
Chua, W., Goldstein, D., Lee, C. K., Dhillon, H. M., Michael, M., Mitchell, P., Clarke, S. J., & Iacopetta, B. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605239 · Cited by 100
Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
Shen, Y., Wang, J., Han, X., Yang, H., Wang, S., Lin, D., & Shi, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081628 · Cited by 101
Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors
Pichler, M., Balić, M., Stadelmeyer, E., Ausch, C., Wild, M., Guelly, C., Bauernhofer, T., Samonigg, H., Höefler, G., & Dandachi, N. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080100 · Cited by 101
Practical Recommendations for Pharmacogenomics-based Prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
Becquemont, L., Alfirevic, A., Amstutz, U., Brauch, H. B., Jacqz-Aigrain, É., Laurent‐Puig, P., Molina‐Vila, M. Á., Niemi, M., Schwab, M. G., Somogyi, A. A., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.147 · Cited by 105
Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection
Dong, L., Wang, S., Fu, B., & Wang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27368-3 · Cited by 102
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?
Gagnière, J., Dupré, A., Gholami, S., Pezet, D., Boerner, T., Gönen, M., Kingham, T. P., Allen, P. J., Balachandran, V. P., DeMatteo, R. P., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002968 · Cited by 101
Liver transplantation for colorectal liver metastases: revisiting the concept
Foss, A. E., Adam, R. A., & Dueland, S. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01097.x · Cited by 100
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
Jensen, L. H., Lindebjerg, J., Pløen, J., Hansen, T. F., & Jakobsen, A. K. M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds008 · Cited by 100
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy
Agrawal, L., Engel, K. B., Greytak, S. R., & Moore, H. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.008 · Cited by 104
Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials
Khattak, M. A., Martin, H. L., Davidson, A., & Phillips, M. R. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.011 · Cited by 99
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
Sobrero, A. F., & Bruzzi, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4162 · Cited by 95
Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors
Tolcher, A. W., Peng, W., & Calvo, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0349 · Cited by 101
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Sood, A., McClain, D., Maitra, R., Basu-Mallick, A., Seetharam, R. N., Kaubisch, A., Rajdev, L. N., Mariadason, J. M., Tanaka, K. E., & Goel, S. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.12.001 · Cited by 100
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
Schilder, R. J., Pathak, H. B., Lokshin, A. E., Holloway, R. W., Alvarez, R. D., Aghajanian, C. A., Min, H., Devarajan, K., Ross, E. A., Drescher, C. W., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.003 · Cited by 99
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
Lee, M. S., McGuffey, E. J., Morris, J. S., Manyam, G. C., Baladandayuthapani, V., Wei, W., Morris, V. K., Overman, M. J., Maru, D. M., Jiang, Z.-Q., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.87 · Cited by 97
Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
Parkinson, D. R., Mccormack, R. T., Keating, S. M., Gutman, S. I., Hamilton, S. R., Mansfield, E. A., Piper, M., Deverka, P. A., Frueh, F. W., Jessup, J. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2961 · Cited by 101
Frequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
Neumann, J. H. L., Zeindl‐Eberhart, E., Kirchner, T., & Jung, A. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1242277 · Cited by 98
Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding
Haga, S. B., Mills, R. A., Pollak, K. I., Rehder, C. W., Buchanan, A. H., Lipkus, I. M., Crow, J. H., & Datto, M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0058-6 · Cited by 98
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Biomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 99
Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery
Denis, J. A., Patroni, A., Guillerm, E., Pépin, D., Benali-Furet, N., Wechsler, J., Manceau, G., Bernard, M., Coulet, F., Larsen, A. K., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.05.009 · Cited by 99
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka‐Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 99
Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
Lurkin, I., Stoehr, R., Hurst, C. D., van Tilborg, A. A. G., Knowles, M. A., Hartmann, A., & Zwarthoff, E. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008802 · Cited by 94
Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients
Malapelle, U., Vigliar, E., Sgariglia, R., Bellevicine, C., Colarossi, L., Vitale, D., Pallante, P., & Troncone, G. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202691 · Cited by 95
KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics
Weichert, W., Schewe, C., Lehmann, A., Sers, C., Denkert, C., Budczies, J., Stenzinger, A., Joos, H., Landt, O., Heiser, V., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090079 · Cited by 97
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor
Pichler, M., Winter, E., Ress, A. L., Bauernhofer, T., Gerger, A., Kiesslich, T., Lax, S., Samonigg, H., & Höefler, G. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201904 · Cited by 97
Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 Chinese patients with Stage I–IV colorectal cancer
Guo, T., Wu, Y., Tan, C., Jin, Y., Sheng, W., Cai, S., Liu, F., & Xu, Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32489 · Cited by 95
A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
Pongor, L. S., Kormos, M., Hatzis, C., Pusztai, L., Szabó, A., & Győrffy, B. (2015) · Genome Medicine · doi:10.1186/s13073-015-0228-1 · Cited by 94
FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Mohelníková-Duchoňová, B. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10316 · Cited by 103
Updated long‐term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy
Kemeny, N. E., Chou, J. F., Boucher, T. M., Capanu, M., DeMatteo, R. P., Jarnagin, W. R., Allen, P. J., Fong, Y. C., Cercek, A., & D'Angelica, M. I. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24189 · Cited by 95
Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives
Pellino, G., Gallo, G., Pallante, P., Capasso, R., Stefano, A. D., Maretto, I., Malapelle, U., Qiu, S., Nikolaou, S., Barina, A., et al. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/2397863 · Cited by 96
A practical guide to biomarkers for the evaluation of colorectal cancer
Chen, W., & Frankel, W. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0136-1 · Cited by 101
Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma
Brody, J. R., Costantino, C. L., Potoczek, M., Cozzitorto, J. A., McCue, P. A., Yeo, C. J., Hruban, R. H., & Witkiewicz, A. K. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.15 · Cited by 94
MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Promoter DNA Methylation of Oncostatin M receptor-β as a Novel Diagnostic and Therapeutic Marker in Colon Cancer
Kim, M. S., Louwagie, J., Carvalho, B. G., Droste, J. S. T. S., Park, H. L., Chae, Y. K., Yamashita, K., Liu, J.-W., Ostrow, K. L., Ling, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006555 · Cited by 93
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds465 · Cited by 95
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras
Vatansever, S., Erman, B., & Gumus, Z. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48029-z · Cited by 89
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Lipsyc, M. D., & Yaeger, R. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.045 · Cited by 93
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
Lamy, A., Blanchard, F., Pessot, F. L., Sesboüé, R., Fiore, F. D., Bossut, J., Fiant, E., Frébourg, T., & Sabourin, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.60 · Cited by 93
Predictive biomarker validation in practice: lessons from real trials
Mandrekar, S. J., & Sargent, D. J. (2010) · Clinical Trials · doi:10.1177/1740774510368574 · Cited by 92
Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations
Holdhoff, M., Schmidt, K., Donehower, R. C., & Diaz, L. A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp240 · Cited by 93
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer EvolutionPreprint
Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026617 · Cited by 94
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
Cohn, A. L., Tabernero, J. M., Maurel, J., Nowara, E., Sastre, J., Chuah, B., Валериевич, К. М., Sakaeva, D., Mitchell, E. P., Dubey, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt057 · Cited by 94
Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium
Brandt, R., Sell, T., Lüthen, M., Uhlitz, F., Klinger, B., Riemer, P., Giesecke‐Thiel, C., Schulze, S., El‐Shimy, I. A., Kunkel, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10954-y · Cited by 92
Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
Pichler, M., Winter, E., Stotz, M., Eberhard, K., Samonigg, H., Lax, S., & Höefler, G. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.175 · Cited by 90
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
Schoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M. L., Franssen, G. M., McBride, W. J., Chang, C.-H., Rossi, E. A., van der Graaf, W. T. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.376 · Cited by 90
Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
Caicedo, C., García‐Velloso, M. J., Lozano, M. D., Labiano, T., Díaz, C. V., López-Picazo, J. M., Gúrpide, A., Zulueta, J. J., Richter, J. Á., & Perez‐Gracia, J. L. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2833-4 · Cited by 93
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
Lacouture, M. E., Anadkat, M. J., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. P. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.004 · Cited by 94
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32408 · Cited by 90
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Köhne, C., & Lenz, H. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0202 · Cited by 91
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 94
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Oberst, M. D., Fuhrmann, S. R., Mulgrew, K. A., Amann, M., Cheng, L., Lutterbuese, P., Richman, L. K., Coats, S., Baeuerle, P. A., & Hammond, S. A. (2014) · mAbs · doi:10.4161/19420862.2014.975660 · Cited by 92
Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing
Borràs, E., Jurado, I., Hernán, I., Gamundi, M. J., Dias, M. M. D. S., Martí, I., Mañé, B., Arcusa, À., Agúndez, J. A. G., Blanca, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-406 · Cited by 88
MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer
Xie, T., Huang, M., Wang, Y., Wang, L., Chen, C., & Chu, X. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452525 · Cited by 90
Changes in mutational status during third‐line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma
Spindler, K. G., Pallisgaard, N., Andersen, R. F., & Jakobsen, A. K. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28863 · Cited by 90
Targeted Therapy for Advanced Colorectal Cancer — More Is Not Always Better
Mayer, R. J. (2009) · New England Journal of Medicine · doi:10.1056/nejme0809343 · Cited by 89
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 88
Circulating Tumor Cells: From Bench to Bedside
Balić, M., Williams, A. J., Lin, H., Datar, R. H., & Côté, R. J. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163404 · Cited by 89
Is personalized medicine finally arriving?
Allison, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0508-509 · Cited by 88
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
Konner, J. A., Schilder, R. J., Derosa, F., Gerst, S. R., Tew, W. P., Sabbatini, P. J., Hensley, M. L., Spriggs, D. R., & Aghajanian, C. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.018 · Cited by 88
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Wang, H. L., Lopategui, J. R., Amin, M. B., & Patterson, S. D. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c6962f · Cited by 90
Self-citation
Tumour molecular profiling for deciding therapy—the French initiative
Nowak, F., Soria, J., & Calvo, F. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.42 · Cited by 87
Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?
Kelley, R. K., & Venook, A. P. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.001 · Cited by 87
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Carrato, A., Abad, A., Massutí, B., Grávalos, C., Escudero, P., Longo-Muñoz, F., Manzano, J.-L., Gómez, A., Safont, M. J., Gallego-Plazas, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.024 · Cited by 87
Panitumumab
Keating, G. M. (2010) · Drugs · doi:10.2165/11205090-000000000-00000 · Cited by 94
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Pietrantonio, F., Cremolini, C., Petrelli, F., Bartolomeo, M. D., Loupakis, F., Maggi, C., Antoniotti, C., de Braud, F., Falcone, A., & Iacovelli, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.016 · Cited by 86
Personalized Sequencing and the Future of Medicine: Discovery, Diagnosis and Defeat of Disease
Esplin, E. D., Oei, L., & Snyder, M. P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.117 · Cited by 91
Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers
Vignot, S., Besse, B., André, F., Spano, J., & Soria, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.002 · Cited by 90
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
Wainberg, Z. A., Lin, L. S., DiCarlo, B. A., Dao, K. M., Patel, R., Park, D., Wang, H.-J., Elashoff, R. M., Ryba, N., & Hecht, J. R. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.280 · Cited by 86
Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 89
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
Helbling, D., Bodoky, G., Gautschi, O. P., Sun, H., Bosman, F. T., Gloor, B., Burkhard, R., Winterhalder, R., Madlung, A., Rauch, D., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds519 · Cited by 86
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
Yoshino, T., Cervantes, A. M. R., Bando, H., Martinelli, E., Oki, E., Xu, R., Mulansari, N. A., Babu, K. G., Lee, M. A., Tan, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101558 · Cited by 91
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 84
Alternate Endpoints for Screening Phase II Studies
Dhani, N. C., Tu, D., Sargent, D. J., Seymour, L., & Moore, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2034 · Cited by 85
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 84
Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagalà, C., Cassano, A., Larocca, L. M., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.028 · Cited by 83
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C. D., Peeters, M., Bazan, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4959 · Cited by 85
Self-citation
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 84
Clinical trial designs incorporating predictive biomarkers
Renfro, L. A., Mallick, H., An, M., Sargent, D. J., & Mandrekar, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.008 · Cited by 85
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
Colomer, C., Margalef, P., Villanueva, A., Vert, A., Pecharromán, I., Solé, L., Gonzàlez‐Farré, M., Alonso‐Marañón, J., Montagut, C. O., Martínez‐Iniesta, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.036 · Cited by 84
Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
Chen, C.-C., Er, T., Liu, Y., Hwang, J., Barrio, M. J., Rodrigo, M., García-Toro, E., & Herreros‐Villanueva, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055793 · Cited by 85
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
oden-Gangloff, A., Fiore, F. D., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière‐Michot, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 90
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 86
Assessing the Clinical Utility of Diagnostics Used in Drug Therapy
Woodcock, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.230 · Cited by 83
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies
Wong, R., & Cunningham, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5024 · Cited by 84
Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
Randomized Phase II Trials: Inevitable or Inadvisable?
Gan, H. K., Grothey, A., Pond, G. R., Moore, M. J., Siu, L. L., & Sargent, D. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3343 · Cited by 82
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Piessevaux, H. H., Buyse, M. E., Roock, W. D., Prenen, H., Schlichting, M., Cutsem, E. V., & Tejpar, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp011 · Cited by 82
MiR‐96‐5p influences cellular growth and is associated with poor survival in colorectal cancer patients
Ress, A. L., Stiegelbauer, V., Winter, E., Schwarzenbacher, D., Kiesslich, T., Lax, S., Jahn, S., Deutsch, A. J. A., Bauernhofer, T., Ling, H. Y., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22218 · Cited by 81
Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas
Damme, N. V., Deron, P. B., Roy, N. V., Demetter, P., Bols, A., Dorpe, J. V., Baert, F., Laethem, J. V., Speleman, F., Pauwels, P., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-189 · Cited by 80
Self-citation

Authors: Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
Affiliations: Ghent University Hospital (BE)
Amgen (United States) (US)
From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
ORCID: Amado, Rafael G.
Peeters, Marc
Siena, Salvatore
Patterson, Scott D.
Chang, David D.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-04-01
Volume: 26
Issue: 10
Pages: 1626-1634
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.7116
OpenAlex: W2106789440
Cited by: 3,207
References: 38
Citations by year: 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
FWCI: 169.59
Type: journal article
Language: en
Update notices: new_edition (2023-06-14)
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: Amgen
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
MeSH terms: Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks